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another were selected. Valvular and non-valvular patients were identiﬁed using appro-
priate ICD-9 codes. A bivariate comparison of baseline characteristics and outcomes 
measures was provided. T-test, Mann Whitney U-test, and chi square test were used 
based on the distribution and standardized differences were calculated. Risk adjust-
ment was done by using the propensity score method with the ProbChoice ™ algo-
rithm. RESULTS: Out of 19,268 identiﬁed patients, 392 were diagnosed with valvular 
atrial ﬁbrillation, and 18, 575 with non-valvular atrial ﬁbrillation. Patients were 
similar in terms of age and gender, but signiﬁcantly different in terms of comorbid 
conditions and baseline CHADS score. Patients with valvular atrial ﬁbrillation were 
more likely to have a Charlson comorbidity score, congestive heart failure, peripheral 
arterial disease, acute coronary syndrome, obesity, etc. Risk-adjusted outpatient visits 
(97% vs. 95%), transient ischemic attack (3.57 vs. 1.76), major bleeding (5.61 vs. 
2.86), and gastrointestinal bleeding (4.59 vs. 1.56) were all higher for patients with 
valvular atrial ﬁbrillation. However, risk-adjusted inpatient hospitalization (39.8% vs. 
44.77%) and osteoporotic fracture (0% vs. 1.66%) were lower. Overall risk-adjusted 
costs did not differ ($15, 426 vs. $16,059). CONCLUSIONS: Most of the adverse 
events analyzed were higher for valvular atrial ﬁbrillation patients relative to non-
valvular atrial ﬁbrillation patients. However, the economic burden of both groups of 
patients on the health care system was similar.
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OBJECTIVES: Patients with atrial ﬁbrillation (AF) are often chronically treated with 
anticoagulant or antiplatelet drugs for stroke prevention and are especially vulnerable 
to bleeding. The objective of this retrospective database analysis was to use administra-
tive claims data from a large, national US health care organization to examine the 
incremental costs of bleeding events in patients with AF. METHODS: Administrative 
claims data were used to identify patients with AF and bleeding events from January 
1, 2002—December 31, 2005 with continuous enrollment for 1 year prior to AF 
diagnosis. Patients were stratiﬁed into 3 sub-cohorts: intracranial hemorrhaging 
(ICH), major bleeds and minor bleeds. To assess incremental costs, patients with 
bleeding were matched on age, gender, region, and month of identiﬁcation to a cohort 
of patients with AF and no evidence of bleeding. Multivariate analyses were used to 
estimate the independent incremental cost attributed to bleeding. RESULTS: A total 
of 127,135 subjects were identiﬁed with AF, 39.1% of whom had bleeding events. 
After applying criteria for continuous enrollment and age (≥18 years), a total of 11,266 
patients that had evidence of bleeding were identiﬁed (1.8% ICH, 10.8% major bleeds 
and 87.4% minor bleeds). Compared to matched controls, patients with ICH or major 
bleed incurred signiﬁcantly more costs over the 1-year follow up period. Mean 
adjusted incremental total costs over the 1-year follow-up period were $258,968 in 
subjects with ICH and $88,775 in subjects with major bleeds. Patients with minor 
bleeds did not incur additional costs compared to controls. CONCLUSIONS: Major 
bleeding associated with AF is associated with signiﬁcant costs over and above that 
of AF alone. New strategies that further reduce the risk of bleeding among patients 
with AF could reduce the cost of their care.
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OBJECTIVES: This study sought to examine the direct medical costs of stroke based 
on the actual hospital charge data in the incidence based cohort. METHODS: We 
obtained the cost data for 884 stroke patients in 8 university hospitals. The cost 
data targeted for all adult patients (≥19 years) admitted for stroke during 2 month 
(between November 1 and December 31, 2006) and were assessed for 2 years. The 
target patients were primarily diagnosed as ‘Subarachnoid hemorrhage (I60)’, ‘Intra-
cerebral hemorrhage (I61)’, ‘Other nontraumatic intracranial hemorrhage (I62)’, 
‘Cerebral infarction (I63)’, and also categorized by history of stroke; ‘primary stroke 
(1st onset)’, ‘recurrent stroke’. RESULTS: According to diagnosis distribution, I60 
was diagnosed in 125 patients (14%), I61 in 158 patients (18%), I62 in 25 patients 
(3%) and I63 in 576 patients (65%). During study period, 85 patients (10%) were 
died and 471 patients (53%) were assessed for more than 1 year. The annual average 
direct medical costs for stroke (I60∼I63) were KRW 8,530,941 for the 1st year of 
onset, KRW 1,098,316 for the 2nd year of onset. This result indicated that the 1st 
year accounted for 89% of 2-year direct medical costs. Analysis by the diagnosis 
class also revealed that the 1st year direct medical costs for hemorrhagic stroke 
(I60∼I62) were KRW 13,518,895, which were more than double of costs for cerebral 
infarction (I63), KRW 5,863,771. The 2nd year costs were similar; KRW 1,055,934 
for hemorrhagic stroke and KRW 1,115,700 for cerebral infarction. When catego-
rized by history of stroke, the 1st year costs for primary stroke (KRW 8,837,111) 
were higher than those for recurrent stroke (KRW 5,988,121). CONCLUSIONS: 
This study is signiﬁcant in that it examined stroke costs including non-reimbursed 
costs based on the actual hospital charge data while previous studies depended on 
the insurance claim data in Korea.
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OBJECTIVES: There is very limited nationally representative data on the economic 
burden of venous thromboembolism (VTE), which manifests as deep vein thrombosis 
(DVT) or pulmonary embolism (PE). The objectives of this study were to assess 
charges and inpatient length of stay associated with DVT and PE among US hospital 
discharges. METHODS: Data were analyzed from the 2007 Nationwide Inpatient 
Sample (NIS), which is the largest all-payer inpatient care database in the U.S. contain-
ing all discharge data from 1044 hospitals in 40 US states, approximating a 20% 
stratiﬁed sample of US community hospitals. Using a combination of several ICD-
9-CM codes, hospital discharges were classiﬁed as those with a primary diagnosis of 
DVT, primary diagnosis of PE, secondary diagnosis of DVT, secondary diagnosis of 
PE and secondary diagnosis of DVT and PE. Hospital charges and length of stay were 
estimated for each of these VTE hospitalizations. RESULTS: Among all the 39,541,948 
hospital discharges in the US in 2007, 172,731 (0.44%) were primary DVT, 155,281 
(0.39%) were primary PE, 402,449 (1.02%) were secondary DVT, 118,557 (0.30%) 
were secondary PE and 30,473 (0.08%) were secondary DVT and PE. The mean 
length of stay for discharges with secondary DVT (11.3 days), secondary PE (12.0 
days), secondary DVT and PE (14.5 days) was substantially more than for discharges 
with primary DVT (4.9 days) and primary PE (5.8 days). Similarly, the mean (95% 
CI) total hospital charges for stays with secondary DVT ($73,152; $68,368–$77,935), 
secondary PE ($80,341; $74,782–$85,900), secondary DVT and PE ($98,205; 
$89,906–$106,503) was substantially more than for stays with primary DVT 
($23,771; $22,572–$24,970) and primary PE ($30,478; $28,912–$32,044). CON-
CLUSIONS: In 2007, the economic burden of VTE in US hospitals was estimated in 
aggregate at $4.07 billion for primary DVT and $4.65 billion for primary PE hospi-
talizations. Compared to primary VTE, the inpatient costs were substantially larger 
for secondary VTE.
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OBJECTIVES: To describe the relationship between the cost-sharing and antihyper-
tensive medication therapy of ﬁxed-dose combination (FDC) versus mono therapy. 
METHODS: Cross-sectional study of all individuals surveyed in the U.S. Medical 
Expenditure Panel Survey 2006 with at least one hypertension diagnosis, only 30 pills 
antihypertensive drugs per prescription, and either FDC or mono therapy were 
included. Bivariate and multivariate generalized linear regression models that con-
trolled for demographic, socioeconomic and drug characteristics assessed the associa-
tion between the costs and therapy type. Crude and adjusted mean out-of-pocket cost 
and total payers paid amount were also computed and compared. The 2006 full-year 
person level sample weight was applied in the statistical analysis. RESULTS: The 
cohort consist of 2,190 hypertension patients with a mean age of 60.3 years, 55.9% 
female, with average Charlson index of 0.36(rang 0–8) and 35% population were on 
FDC therapy. The multivariate model that adjusted for demographic, socioeconomic 
and drug factors, showed FDC therapy had no signiﬁcant association with out-of-
pocket cost with coefﬁcient(95% conﬁdential interval) of 1.0742(−0.9577 to 3.1061), 
but was negatively associated with the total cost with coefﬁcient of −6.6614(−10.1180 
to −3.2048). The crude average increase in out-of-pocket and total payer costs per 
patient with 30 pills per prescription between FDC versus mono therapy were 
$6.22(95% conﬁdence interval, $4.42 to 8.02) and $5.67($2.66 to 8.67), respectively, 
while the adjusted average increase in costs were $1.47($−0.29 to 3.23) and $2.00($−
1.02 to 5.01), respectively. CONCLUSIONS: The association results suggested that 
FDC antihypertensive therapy does not affect patient out-of-pocket cost, but FDC 
therapy reduces payer cost. Considering the number of agents in one pill of the 
therapy, FDC therapy does not cost signiﬁcantly more to patient and payer than mono 
therapy. Our results also provide economic evidence for clinicians to help ease the 
ﬁnancial burden from out-of-pocket cost in patients who need two antihypertensive 
agents therapy.
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OBJECTIVES: To summarize economic burden associated with treatment of venous 
thromboembolism (VTE) from payor, patient, and caregiver perspectives by assessing 
characteristics, outcomes, costs, and cost drivers of treatment. METHODS: We con-
ducted a systematic search of MEDLINE and EMBASE databases for US economic 
studies of VTE published between January 1, 1999 and May 22, 2009. We also 
reviewed bibliographies of included studies. Studies were critically appraised using the 
